Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Sweeney C, Marshall GS. United States physicians' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024 Feb 13. doi: 10.1016/j.jadohealth.2023.11.394
Browning JC, Cartwright M, Thorla, Jr. I, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023 Jan;24(1):119-33. doi: 10.1007/s40257-022-00733-9
Goswami S, Korgaonkar S, Bhattacharya K, Rosenthal M. Food insecurity in a sample of informal caregivers in 4 southern US states. Prev Chronic Dis. 2022 Aug 18;19:E51. doi: 10.5888/pcd19.220069
Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. National and state-level composite completion of recommended vaccines among adolescents in the United States, 2015-2018. J Adolesc Health. 2021 Nov;69(5):762-8. doi: 10.1016/j.jadohealth.2021.07.020
Kurosky SK, Esterberg E, Irwin DE, Trantham L, Packnett E, Novy P, Whelan J, Hogea C. Meningococcal vaccination among adolescents in the United States: a tale of two age platforms. J Adolesc Health. 2019 Jul;65(1):107-15. doi: 10.1016/j.jadohealth.2019.02.014
Augustin M, Mcbride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Hollis K, Proctor C, Mcbride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8
Calancie L, Anderson S, Branscomb J, Apostolico AA, Hassmiller Lich K. Using behavior over time graphs to spur systems thinking among public health practitioners. Prev Chronic Dis. 2018 Feb 1;15:E16. doi: 10.5888/pcd15.170254
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, Mcbride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Mansfield C, Tangka FKL, Ekwueme DU, Smith JL, Guy GP, Li C, Hauber AB. Stated preference for cancer screening: a systematic review of the literature, 1990–2013. Prev Chronic Dis. 2016 Feb 25;13:E27. doi: 10.5888/pcd13.150433
McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.
Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003 Feb 1;4(2):131-9.